» Articles » PMID: 1552912

Characteristics and Prognostic Implications of Myosin Missense Mutations in Familial Hypertrophic Cardiomyopathy

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1992 Apr 23
PMID 1552912
Citations 166
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Familial hypertrophic cardiomyopathy is characterized by a variable degree of myocardial hypertrophy and a wide range of symptoms. Different mutations in the beta cardiac myosin heavy-chain gene have been identified in three affected families. However, neither the proportion of cases attributable to myosin mutations nor the effects of different mutations on clinical outcome are known.

Methods: Using a ribonuclease protection assay, we screened the beta cardiac myosin heavy-chain genes of probands from 25 unrelated families with familial hypertrophic cardiomyopathy; this assay is a sensitive method for detecting the presence and location of mutations. We further defined the mutations by analyzing their nucleotide sequences. The clinical features of the disease were compared in families with various myosin mutations.

Results: Seven mutations in the beta cardiac myosin heavy-chain gene were identified in 12 of the 25 families. All were missense mutations (i.e., causing the substitution of a single amino acid) clustered in the head and head-rod junction regions of the molecule. Six mutations resulted in a change in the charge of the amino acid. Patients with mutations that changed the charge of the altered amino acid (such as that from arginine to glutamine at nucleotide 403 or from arginine to cysteine at nucleotide 453) had a significantly shorter life expectancy (mean age at death, 33 years), whereas patients with the one mutation that did not produce a change in charge (Val606Met) had nearly normal survival. However, patients with different mutations did not differ appreciably in their clinical manifestations of familial hypertrophic cardiomyopathy.

Conclusions: Different missense mutations in the beta cardiac myosin heavy-chain gene can be identified in approximately 50 percent of families with hypertrophic cardiomyopathy. In those families, a definite genetic diagnosis can be made in all members. Since the location of a mutation or its DNA-sequence alteration (or both) appears to influence survival, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members.

Citing Articles

Mavacamten inhibits myosin activity by stabilising the myosin interacting-heads motif and stalling motor force generation.

McMillan S, Pitts J, Barua B, Winkelmann D, Scarff C bioRxiv. 2025; .

PMID: 39990378 PMC: 11844505. DOI: 10.1101/2025.02.12.637875.


Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities.

Sequeira V, Waddingham M, Tsuchimochi H, Maack C, Pearson J J Mol Cell Cardiol Plus. 2025; 4():100036.

PMID: 39801694 PMC: 11708264. DOI: 10.1016/j.jmccpl.2023.100036.


Global, regional, and national burdens of heart failure in adolescents and young adults aged 10-24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021.

Yang C, Jia Y, Zhang C, Jin Z, Ma Y, Bi X EClinicalMedicine. 2024; 79:102998.

PMID: 39737218 PMC: 11683260. DOI: 10.1016/j.eclinm.2024.102998.


Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.

Verheyen N, Auer J, Bonaros N, Buchacher T, Dalos D, Grimm M Wien Klin Wochenschr. 2024; 136(Suppl 15):571-597.

PMID: 39352517 PMC: 11445290. DOI: 10.1007/s00508-024-02442-1.


Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice.

Lopes L, Ho C, Elliott P Eur Heart J. 2024; 45(30):2727-2734.

PMID: 38984491 PMC: 11313585. DOI: 10.1093/eurheartj/ehae421.